Integration of Patient-Reported Outcomes (PROs) and the Patient Voice: A Review of 6 Health Technology Assessment (HTA) Agencies
Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments
Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions
Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model
The Evolving Healthcare Landscape and the Impact on Patient Access and Affordability
Managing the Growing Expansion of Copay Accumulators
Medicare Part B: Do Providers Choose Treatment Based on Payment?
What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.
Xcenda Collaborated with MAPRx to Publish New Report Addressing Medicare Part D Challenges to Beneficiaries
Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments
Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?
Emerging Trends in PBM Restrictions on Commercial Copay Assistance
How Policy Impacts Patient Support
What role does the changing healthcare coverage landscape play in support program demand and design?
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
Applying Cost-Effectiveness Thresholds to the Real World: Implications on Access for Medicare Beneficiaries
Payer Tactics to Manage Commercial Copay Assistance Gaining Traction